-
Electronic (PDF)
-
Site License
-
Enterprisewide
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2012
Global Markets Direct, September 2012, Pages: 45
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL). Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL).
- A review of the Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) 7
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics under Development by Companies 9
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics – Products under Development by Companies 14
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Development 16
Abbott Laboratories 16
Santaris Pharma A/S 17
Pharmacyclics, Inc. 18
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
navitoclax - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ibrutinib - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
SPC-2996 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ABT-263 + Fludarabine + Cyclophosphamide + Rituximab - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ABT-263 + Bendamustine + Rituximab - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ABT-199 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Clofarabine + Cytarabine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics – Drug Profile Updates 38
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Dormant Products 42
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) – Product Development Milestones 43
Featured News & Press Releases 43
Aug 01, 2012: Pharmacyclics To Receive $50m Milestone Payment From Janssen Biotech 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45
List of Tables
Number of Products Under Development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL), H2 2012 7
Products under Development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Abbott Laboratories, H2 2012 16
Santaris Pharma A/S, H2 2012 17
Pharmacyclics, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics – Drug Profile Updates 38
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics – Dormant Products 42
List of Figures
Number of Products under Development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL), H2 2012 7
Products under Development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
